HOME >> MEDICINE >> NEWS
JCI table of contents, May 11, 2006

EDITOR'S PICK

A bone of contention in drug-induced osteomalacia

Long-term therapy with some antiepileptic drugs and antibiotics can cause osteomalacia, a condition marked by softening of the bones that is usually the result of vitamin D and calcium deficiency. However, the molecular mechanism of drug-induced osteomalacia remains unclear. In a study appearing online on May 11 in advance of print publication in the June issue of the Journal of Clinical Investigation, Kenneth Thummel and colleagues from the University of Washington report that the adverse effect on bone mineral density of these drugs occurs through their activation of the steroid and xenobiotic receptor (SXR), which induces expression of the enzyme CYP3A4 that breaks down vitamin D, diminishing its beneficial effects on bone, and resulting in osteomalacia.

The biologically active forms of vitamin D are broken down to biologically inactive products by the enzyme CYP24, which itself is regulated by the vitamin D receptor (VDR). A 2005 study by another research group that also appeared in the JCI reported that activation of SXR induced CYP24 expression in mice, which would explain an increase in vitamin D breakdown and the resulting osteomalacia observed in individuals taking some SXR-activating antiepileptic drugs or antibiotics. In contrast, the current study by Thummel et al. found that SXR does not induce CYP24 expression in mice to any appreciable extent. Instead, SXR inhibited VDR-mediated CYP24 activity. They also found that treatment of humans with the SXR-activating antibiotic rifampicin had no effect on CYP24 expression, but did increase expression of another enzyme that breaks down vitamin D CYP3A4. The authors conclude that while SXR negatively regulates CYP24 expression and subsequent vitamin D breakdown, it can also enhance vitamin D hydroxylation and breakdown by inducing the expression of CYP3A4. This explains how SXR activators can cause osteomalacia. The s
'"/>

Contact: Brooke Grindlinger
press_releases@the-jci.org
212-342-9006
Journal of Clinical Investigation
11-May-2006


Page: 1 2 3 4 5 6

Related medicine news :

1. International symposium on fruit, vegetables headed for Houston
2. Stevens Roundtable: Health, Technology & Society, July 11
3. FDA approves ZYFLO CR extended-release tablets for chronic treatment of asthma
4. Once-fatal metabolic disorders treatable, says Stanford/Packard researcher
5. Clinical review -- A psychological approach to the management of irritable bowel syndrome
6. JCI table of contents -- May 17, 2007
7. JCI table of contents: May 10, 2007
8. New treatments needed for irritable bowel syndrome
9. JCI table of contents: May 1, 2007
10. Americans still not eating enough fruits and vegetables, according to 2 recent studies
11. Slow-release morphine reduces level of intractable cough

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: JCI table contents May

(Date:6/18/2013)... The new swab, designed for infants ... the tip allowing for faster collection of infant saliva. ... (SIS) can be tested for cortisol, cotinine, testosterone, ... diameter of the Salimetrics Infant Swab has been increased ... access more saliva in the newborn’s mouth and thereby ...
(Date:6/17/2013)... (PRWEB) June 18, 2013 A ground-breaking ... stroke patients a new rehabilitation treatment. , Constraint ... and offers a new intensive rehabilitation program to help ... those with cerebral palsy and some other neurological conditions. ... “rewires” the brain helping people to improve the use ...
(Date:6/17/2013)... IL (PRWEB) June 17, 2013 The ... after mild traumatic brain injury (MTBI) closely resembles that ... study published online in the journal Radiology. , ... seen in early Alzheimer’s dementia,” said the study’s lead ... the Division of Neuroradiology at the University of Pittsburgh ...
(Date:6/17/2013)... Essential tremor (ET) is the most common ... people in the United States, and millions more worldwide. ... causes ET, there are no medications specifically designed to ... Tremor© is the International Essential Tremor Foundation’s annual research ... cure for this life-altering neurological condition. , “Although millions ...
(Date:6/17/2013)... distribution of white matter brain abnormalities in some patients ... found in early Alzheimer,s dementia, according to a new ... , "Findings of MTBI bear a striking resemblance ... study,s lead author, Saeed Fakhran, M.D., assistant professor of ... of Pittsburgh School of Medicine. "Additional research may help ...
Breaking Medicine News(10 mins):Health News:Salimetrics Redesigns Infant Swab for Faster, Easier Collection 2Health News:Revolutionary Treatment for Stroke Now Available in Western Australia 2Health News:RSNA: Concussion Patients Show Alzheimer’s-like Brain Abnormalities 2Health News:RSNA: Concussion Patients Show Alzheimer’s-like Brain Abnormalities 3Health News:RSNA: Concussion Patients Show Alzheimer’s-like Brain Abnormalities 4Health News:International Essential Tremor Foundation Kicks Off Annual Essential Tremor Research Fundraiser, Tulips for Tremor 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 2Health News:Concussion patients show Alzheimer's-like brain abnormalities 3
(Date:6/17/2013)... 2013 Breezy , a portfolio ... product this week using a platform technology enabling innovative treatment ... (bad breath) is being sold in major Israeli pharmacy chains ... launch in Israel follows similar successful ... Spain earlier this year, with a repeat ...
(Date:6/17/2013)... NEW BRUNSWICK, N.J. , June 17, 2013 ... JNJ ) announced today a definitive agreement to ... and development company focused on drugs to treat ... Aragon,s androgen receptor antagonist program.  Aragon,s lead product ... inhibitor, ARN-509, in Phase 2 development for castration ...
(Date:6/17/2013)... 2013  Imprimis Pharmaceuticals, Inc. (NASDAQ: ... acquisition of intellectual property (IP) rights related to ... of Ohio -based Buderer Drug ... commercial development of these proprietary innovations and also ... on additional Buderer Drug Company intellectual property and ...
Breaking Medicine Technology:A Big "LIKE" for Oral Hygiene 2Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. 2Johnson & Johnson Announces Definitive Agreement To Acquire Aragon Pharmaceuticals, Inc. 3Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 2Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 3Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 4Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property Assets from Buderer Drug Company 5
Cached News: